Loading
Led KEYNOTE-040, which showed pembrolizumab improves survival in previously treated head and neck cancer.
Ezra Cohen was principal investigator of KEYNOTE-040, the randomised trial showing pembrolizumab improves overall survival over standard chemotherapy in platinum-refractory head and neck squamous cell carcinoma, and led the SITC consensus on immunotherapy in the disease. He has also led targeted therapy trials in thyroid cancer and chairs the head and neck section of major cooperative groups.
Shares PD-1, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tags head-and-neck, immunotherapy.
Shares UC San Diego Moores Cancer Center, PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag head-and-neck.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, immunotherapy.